tbuckley/cabot-search huggingface dataset:
A phase II trial of docetaxel and irinotecan (DI) in children and young adults with recurrent or refractory Ewing sarcoma family of tumor (ESFT).
Authors: Jong Hyung Yoon, Hyeon Jin Park, Byung-Kiu Park
Journal: Journal of Clinical Oncology (2012)

9579 Background: Patients with ESFT resistant to second-line therapy, such as topotecan plus cyclophosphamide, have a dismal prognosis and few therapeutic options. Docetaxel (D), a microtubule inhibitor, demonstrated activity in patients with ESFT (Zwerdling T et al. Cancer 2006:106:1821-1828). Irinotecan (I), a toposiomerase I inhibitor, is being evaluated in clinical trials for ESFT. Despite the different mechanisms of action of D and I, and their activities as a single-agent against ESFT, DI combination has not been previously evaluated in ESFT. Thus, we prospectively performed a single-arm, phase II trial of DI in a single center in Korea. Methods: Patients &lt;30 years with ESFT, who failed second-line therapy, were eligible for the study. D was administered IV over 60 minutes at a dose of 100 mg/m 2 on Day 1, and I at a dose of 80 mg/m 2 over 90 minutes on Days 1 and 8 of a 21-day cycle until disease progression. The primary end-point was objective response assessed by RECIST; the secondary end-point was safety. All toxicities were graded according to the National Cancer Institute’s Common Toxicity Criteria (version 4.0). Results: Of seven eligible patients (4 males; median age, 17 years (range 5-21)), 4 were recurrent/refractory cases, and 3 refractory cases. Median number of previous regimens was 6 (range 3-6). One CR, 1 PR, and 5 PD were obtained by DI combination (median number of cycles, 2 (range 1-15)), with objective response (CR+PR) rate of 2/7 (28.6%). One patient with PR achieved CR with subsequent surgery. CR of these two patients lasted 8.9 months and 10.6 months. Of all seven patients fully evaluable for toxicity, grade 4 neutropenia occurred in 7 (100%); grade 3 and 4 thrombocytopenia in 1 (14%) and 6 (86%), respectively; grade 3 pericardial effusion, paresthesia, motor weakness, oral mucositis, each in one (14%). Two patients required ≥1 dose delay; 2 required ≥1 dose reduction due to adverse events, but no one experienced treatment-related mortality. Conclusions: DI combination demonstrated activity in children and young adults with ESFT who were heavily pre-treated, and was feasible.
The Auxiliary Calcium Channel Subunit α2δ4 Is Required for Axonal Elaboration, Synaptic Transmission, and Wiring of Rod Photoreceptors
Authors: Yuchen Wang, Katherine E. Fehlhaber, Ignacio Sarria, Yan Cao, Norianne T. Ingram, Debbie Guerrero-Given, Ben Throesch, Kristin Baldwin, Naomi Kamasawa, Toshihisa Ohtsuka, Alapakkam P. Sampath, Kirill A. Martemyanov
Journal: Neuron (2017)
Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: An Economic Analysis.
Authors: Michael Schwarzinger, Celine Beauchamp, Sebastien Maury, Cecile Pautas, Anne Vekhoff, Hassan Farhat, Felipe Suarez, François Hemery, Mathieu Kuentz, Patrick Maison, Catherine Cordonnier
Journal: Blood (2006)
Adult granulosa cell tumors (GCT): 56 years of clinicopathologic outcomes including FOXL2 mutational status.
Authors: Michelle Wilson, Roseanne Rosario, Kathryn F. Chrystal, Kathryn Payne, Barrie David Evans, Andrew Shelling, Peter C.C. Fong
Journal: Journal of Clinical Oncology (2013)

5536 Background: GCT account for 2-3% of ovarian cancers with a tendency for late relapse. Treatment is primarily surgical. The role of chemotherapy and hormonal therapy is more controversial. The FOXL2 mutation (402C→G) has been identified as a potential driver mutation and may be useful in diagnosis and treatment. Methods: We performed a retrospective review of GCT patients (pts) referred to the Auckland Gynae-Oncology Multidisciplinary Team from 1955 to 2011. Baseline characteristics, clinical course, histopathology and survival data was recorded. FOXL2 mutation status was determined by DNA sequencing, and correlated with clinical data. Results: 56 GCT pts were identified. Median (med) age 48.6 years (y) (22-86). Stage I were 82.1%. 48% of tumours were ≥10cm. Med follow up was 10.0y (0.2-40.4). 25 pts progressed, med time to progression (TTP) was 4.5y (0.1-17.7). Med progression free survival was 14.5y. Med overall survival (OS) was 21.8y but med disease specific survival was not reached. 9/18 pts died of disease. Stage III GCT and size ≥10cm had a higher risk of relapse (RR 3.1 and 2.9) and death (RR 8.2 and 8.6) respectively. 17/46 (37%) Stage I pts progressed. Med TTP was 8.3y (1.3 to 17.7), med OS was 29.0y. Stage I relapse rate was higher in tumours ≥10cm (RR 3.9 p&lt;0.01). 12/17 1 st relapses were treated with surgery. 10/17 pts received ≥1 line of chemotherapy and 7 ≥1 hormonal therapy. Clinical benefit rates (CR, PR and SD&gt;6m) for first-line chemotherapy was 25% and 71% for hormones. All 7 Stage III pts progressed with med OS of 6.3yr (0.2-12.3y). Currently the FOXL2 mutation statuses are known for 18 patients. 89% carried the mutation. Homozygous, heterozygous and wild-type mutations had no difference in risk of relapse or death. Further FOXL2 mutation analysis is ongoing. Conclusions: This long term series confirms the protracted natural history of this disease. Early stage GCT, despite progression has a good prognosis with med OS &gt;25y. Stage and tumour size remain the most consistent prognostic factors. Whilst surgery remains the mainstay of therapy, the high response rate to hormonal therapy deserves investigation. Currently the FOXL2 mutation status does not appear prognostic but this needs further research.
Minimally Invasive, Laparoscopic, and Robotic-assisted Techniques Versus Open Techniques for Kidney Transplant Recipients: A Systematic Review
Authors: Sven Wagenaar, Johanna H. Nederhoed, Arjan W.J. Hoksbergen, H. Jaap Bonjer, Willem Wisselink, Gabrielle H. van Ramshorst
Journal: European Urology (2017)
Abstract P2-05-15: The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
Authors: M He, Y-Z Jiang, L-C Tang, Y-L Chen, Z-M Shao, G-H Di
Journal: Cancer Research (2017)

Abstract Purpose: To evaluate the prognostic value of the lymph node ratio (LNR) in patients with axillary lymph node-positive triple-negative breast cancer (TNBC). Patients and methods: Based on X-tile plots, we classified women into low-, medium-, and high-risk LNR groups. Univariate and multivariate Cox proportional hazards regression analyses for overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS) were performed. The prognostic efficacy of the LNR was investigated in the first cohort from the Surveillance, Epidemiology, and End Results (SEER) database (n=4114) and was further validated in an independent cohort from Fudan University Shanghai Cancer Center (n=417). Results: The patients were classified into low- (≤0.30), medium- (0.30 to 0.70) and high-risk (&amp;gt;0.70) LNR groups. Multivariate analysis revealed that the LNR was an independent predictor of OS (hazard ratio (HR) for high-risk LNR: 3.24; 95% confidence interval (CI): 2.56 to 4.09) and BCSS (HR for high-risk LNR: 3.57; 95% CI: 2.76 to 4.62) in the SEER population and also for DFS (HR for high-risk LNR: 4.29; 95% CI: 2.24-8.21) in the validation population. Subgroup analysis revealed that patient classification according to the LNR could discriminate among groups of patients with different survival rates based on pN staging. Effect of Lymph Node Ratio and pN Classification on Survival Among Patients from SEERVariableOSBCSS HR a(95% CI)PHR a(95% CI)PLymph node ratio Low,≤0.301-1-Medium, &amp;gt;0.30 and ≤0.702.05(1.63-2.59)&amp;lt;0.0012.26(1.75-2.92)&amp;lt;0.001High,&amp;gt;0.703.24(2.56-4.09)&amp;lt;0.0013.57(2.76-4.62)&amp;lt;0.001pN N11-1-N21.53(1.21-1.93)&amp;lt;0.0011.63(1.27-2.10)0.001N32.72(2.14-3.46)&amp;lt;0.0012.97(2.29-3.85)&amp;lt;0.001a Cox proportional hazards model. Hazard ratios are adjusted for age, race, histologic grade, tumor size, surgery type and radiotherapy. Conclusion: The LNR shows potential for use as an additional prognostic factor for TNBC patients with positive lymph node involvement. Considering the heterogeneity of TNBC, use of the LNR might allow for optimization of the pN staging system, and this ratio should be considered when making treatment decisions. Citation Format: He M, Jiang Y-Z, Tang L-C, Chen Y-L, Shao Z-M, Di G-H. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-15.
Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.
Authors: Melissa Alsina, Rachid Baz, Jose L Ochoa, Jyotishankar Raychaudhuri, Kara Kosakowski, Michelle Mintz, Kendra Anderson, William S Dalton, Daniel Sullivan
Journal: Blood (2009)
NK Cytotoxicity in Vitro and NK/ MDSCs/Tcell Subpopulations in AML/MDS Patients on 5-Azacytidine Treatment
Authors: Maria Tsirogianni, Eirini Grigoriou, Kleopatra Dagla, Vassiliki Pappa, Evi Konsta, Violetta Kapsimali-Vaiopoulou, Nora-Athina Viniou, Katerina Psarra, Panagiotis Tsirigotis
Journal: Blood (2016)
Detection of Translocation t(7;12)(q36;p13) in Infants with Acute Myeloid Leukemia By Novel 3-Color Fluorescent in Situ Hybridization Approach
Authors: Grigory Tsaur, Olga Plekhanova, Elena Fleischman, Elena Volochnik, Olga Sokova, Anatoly Kustanovich, Irina Kalinina, Alexander Popov, Leonid Saveliev, Egor Shorikov, Larisa Fechina
Journal: Blood (2015)
Effect of C6Ceramide on chemotoxicity of gemcitabine against chemoresistant pancreatic cell lines.
Authors: Harold J. Wanebo, Andrew Liss, Wayne Bowen
Journal: Journal of Clinical Oncology (2015)

e15286 Background: Pancreatic cancer is a highly chemo-resistant malignancy with 5% overall survival, and limited treatment options with chemotherapy (Gemcitabine) and surgical resection possible in < 20% of patients with post resection survival of only 15-20%. Our studies suggest potential value of C6 Ceramide as a chemo enhancing biologic in therapy of chemoresistant pancreatic cancer. C6 Ceramide is an active sphingomyelin end product that has the major biologic function of inducing apoptosis in cells compromised or damaged by injury or malignancy, and appears to have potential value in therapy of malignancy. We have demonstrated C6 Ceramide inhibition of pro survival (AKT/PI3K/mTOR) and KRAS mutant pathways, which promote pancreatic cancer growth and metastases. Methods: Cell lines obtained from 4 freshly cultured pancreatic cancers, and 3 well established cancer cell lines (ATCC) were cultured in 96 well plates, 4000 cells/well, and were treated at 24 hours with Gemcitabine in 0.9% NaCl (1,2,5,10 ug/ml), alone and with C6 Ceramide in DMSO (2.5, 5.0, 10 ug/ml) and two liposomal formulations of C6 Ceramide: (galloyl) DPC6: D0PC: C6 Ceramide (0.5, 1.0 ,2.0 ug/ml), and (pegylated) 180 PEG 2PE: D0PC: C6 Ceramide (0.5, 1.0, 2.0 ug/ml), and included vehicle controls. Cell viability was assessed by resazurin assay, 48 hour post drug infusion. Results: As noted in Figure 1, the effect of treatment on freshly cultured cell lines (722, 1108, 1312, and 1513) showed marked cell growth inhibition with combination C6 Ceramide and Gemcitabine (cell death 60-80%). This result was also replicated in all of the 3 ATC based cells (long term cultured). Conclusions: C6 Ceramide appears to potentiate chemotoxicity of Gemcitabine against all (freshly cultured and long term cultured) pancreatic cancer cell lines, suggesting clinical value in continued development of C6 Ceramide as an anti-cancer biologic.
Four Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid Leukemia Patients.
Authors: Stefania Paolini, Sarah Parisi, Anna Candoni, Pier Paolo Piccaluga, Michele Gottardi, Claudio Laterza, Cristina Papayannidis, Emanuela Ottaviani, Nicoletta Testoni, Antonio Curti, Carlo Finelli, Nicola Vianelli, Ilaria Iacobucci, Federica Salmi, Barbara Lama, Filippo Gherlinzoni, Renato Fanin, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2009)
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Results of the SHIVA trial.
Authors: Christophe Le Tourneau, Jean-Pierre Delord, Anthony Goncalves, Celine Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Tredan, Cecile Mauborgne, Sebastien Armanet, Nicolas Servant, Ivan Bieche, Virginie Bernard, David Gentien, Pascal Jézéquel, Valéry Attignon, Sandrine Boyault, Anne Vincent-Salomon, Maud Kamal, Xavier Paoletti
Journal: Journal of Clinical Oncology (2015)

11113 Background: Non-randomized studies suggested that selecting molecularly targeted agents (MTAs) based on the molecular profile of pts’ tumors, independently of tumor location and histology, improves outcome. We evaluated this histology-agnostic approach in pts who have failed standard of care therapy. Methods: Eligible pts underwent a biopsy of a metastatic site in order to establish the molecular profile of their tumor. Pts for whom a molecular alteration was identified and matched a MTA according to a pre-specified treatment algorithm (Table), were stratified according to the molecular pathway and randomly allocated to matching MTA or treatment at physician’s choice (TPC). MTAs were only allowed outside their licensed indication and if not previously given. The primary end point was PFS. Results: Among 741 included pts, 195 were randomized. 82, 89 and 24 pts were allocated to the HT, PI3K and RTK/MAPK subgroups. G3/4 AEs rates were 43% and 35% in the MTA and TPC arms. ORR was 4.1% in the MTA arm vs 3.4% in the TPC arm. Global PFS and according to the molecular pathway are presented in the Table. Conclusions: The SHIVA trial did not demonstrate that the administration of MTAs outside their indications according to the pre-specified treatment algorithm improves PFS as compared to TPC in heavily pretreated pts. This histology-agnostic approach warrants further investigation in the RTK/MAPK pathway. Clinical trial information: NCT01771458. Median PFS (months) Molecular pathways Molecular alterations MTAs TPC arm (n = 96) MTA arm (n = 99) HR [95%CI] p-value All patients 2.0 2.3 0.88 [0.65-1.19] 0.41 Hormonal (HT) AR protein expression > 10% ER/PR protein expression > 10% Abiraterone Tamoxifen or Letrozole 2.0 2.1 1.12 [0.70-1.78] 0.64 PI3K/AKT/mTOR (PI3K) PI3KCA/AKT1 mut/amplif AKT2,3/mTOR/RAPTOR/RICTOR amplif PTEN/STK11 mut/LOH Everolimus 1.9 2.4 0.79 [0.51-1.24] 0.30 RTK/MAP kinase (RTK/MAPK) PDGFRA or B/FLT3 mut/amplif KIT/ABL/RET mut/amplif HER-2 mut/amplif BRAF mut/amplif EGFR mut/amplif SRC mut/amplif EPHA2/LCK/YES amplif Sorafenib Imatinib Lapatinib+ Trastuzumab Vemurafenib Erlotinib Dasatinib 2.0 3.7 0.58 [0.24-1.37] 0.20
Detection of human papillomavirus in vulva cancer tissue.
Authors: Anna v Antonets, Galina Nerodo, Konstantin v Dvadnenko, Tatyana A Zykova, Natalya V Ohremenko, Ekaterina Alekseevna Nerodo
Journal: Journal of Clinical Oncology (2013)

e16514 Background: Human Papillomavirus (HPV) status of the patients with vulva cancer was investigated retrospectively. Methods: We detected HPV of high cancerogenic risk (16, 18, 31, 33, 35, 45, 51, 52, 58, 59 types) in archival paraffin-embedded vulva cancer tissue of 58 patients aged from 26 to 82 years with I-IV grades. The extraction of DNA was performed with classical phenol-chloroform laboratory technic for further real-time PCR analysis (with HPV screening and HPV genotype kits of Amplisens). Results: HPV DNA was found out in 12 patients (20.6%). Among these patients 8 from 10 women (80%) belong to the group of reproductive age (26-50 years) whilst 4 from 48 (8.33%) were seniors. HPV of 16 type presented in 50%, HPV of 16 and 18 types – in 50% of all HPV positive patients of reproductive age. Among elderly patients 50 % had HPV of 16 type, 50 % - 16 and 31 types. Conclusions: Our investigations confirm the existence of two pathogenic variants of vulva cancer. For young age group there are up to 80% of HPV positive patients. The second elderly group (50-82 years) is not related with infection, there are only 8% of HPV positive patients.
Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia
Authors: Hui Yang, Zachary S. Bohannan, Zhihong Fang, Irene Gañán-Gómez, Yue Wei, Linda J. Paradiso, Hiroyuki Iwamura, Guillermo Garcia-Manero
Journal: Blood (2016)
Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group
Authors: Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, Susana C. Raimondi, Betsy Hirsch, Janet Franklin, Beverly Lange, Soheil Meshinchi
Journal: Blood (2008)
Outcome of Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia in Third Complete Remission (CR3): A Vital Role for Graft-Versus-Host-Disease/Graft-Versus-Leukemia Effect in Survival.
Authors: Adam Gassas, Kashif Ishaqi, John Doyle
Journal: Blood (2006)
Combinatorial Therapies After Spinal Cord Injury: How Can Biomaterials Help?
Authors: Tobias Führmann, Priya N. Anandakumaran, Molly S. Shoichet
Journal: Advanced Healthcare Materials (2017)

Traumatic spinal cord injury (SCI) results in an immediate loss of motor and sensory function below the injury site and is associated with a poor prognosis. The inhibitory environment that develops in response to the injury is mainly due to local expression of inhibitory factors, scarring and the formation of cystic cavitations, all of which limit the regenerative capacity of endogenous or transplanted cells. Strategies that demonstrate promising results induce a change in the microenvironment at‐ and around the lesion site to promote endogenous cell repair, including axonal regeneration or the integration of transplanted cells. To date, many of these strategies target only a single aspect of SCI; however, the multifaceted nature of SCI suggests that combinatorial strategies will likely be more effective. Biomaterials are a key component of combinatorial strategies, as they have the potential to deliver drugs locally over a prolonged period of time and aid in cell survival, integration and differentiation. Here we summarize the advantages and limitations of widely used strategies to promote recovery after injury and highlight recent research where biomaterials aided combinatorial strategies to overcome some of the barriers of spinal cord regeneration.
Abstract IA02: Advances in drug delivery
Authors: Robert S. Langer
Journal: Cancer Research (2017)

Abstract Advanced drug delivery systems are having an enormous impact on human health. We start by discussing our early research on developing the first controlled release systems for macromolecules and the isolation of angiogenesis inhibitors and how these led to numerous new cancer therapies. New drug delivery technologies including nanoparticles and nanotechnology are now being studied for use treating cancer and other illnesses. We will also discuss novel super long acting oral drug delivery systems as well as ways of developing novel microchips for drug delivery and how they also can be used for designing personalized cancer drug regimens. Finally, we will discuss new approaches for cell therapy based on a novel method of “squeezing” materials into cells. Citation Format: Robert S. Langer. Advances in drug delivery. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr IA02.
Randomized, Double Blind Trial of 6 Versus 12 Months Of Dual Antiplatelet Therapy After DES-Implantation (ISAR-SAFE)
Authors: Stefanie Schuepke, Julinda Mehilli, Karl-Ludwig Laugwitz, Franz-Josef Neumann, Jurrien M ten Berg, Tom Adriaenssens, Yaling Han, Barbara von Merzljak, Gert Richardt, Melchior Seyfarth, Klaus Tiroch, Tanja Morath, Michael Maeng, Bernhard Zrenner, Nonlag Rifatov, Claudius Jacobshagen, Harald Mudra, Eberhard Freiherr von Hodenberg, Jochen Woehrle, Sebastian Kufner, Christian Hengstenberg, Marcus Fischer, Martin Schmidt, Franz Dotzer, Tareq Ibrahim, Peter Sick, Christoph A Nienaber, Arnoud W van 't Hof, Takeshi Kimura, Bernhard Witzenbichler, Stephan Windecker, Heribert Schunkert, Adnan Kastrati
Journal: Circulation (2014)
Abstract B30: Establishment and maintenance of a PDX Core Facility
Authors: Marissa Mattar, Rajesh K. Uthamanthil, Elisa de Stanchina
Journal: Clinical Cancer Research (2016)

Abstract Patient Derived Xenografts (PDX) are a powerful technology with the potential to unlock key mechanisms of disease for a variety of difficult to treat cancers and cancers with no applicable laboratory models. These models have a wealth of potential applications in tumor genetics, biomarker discovery, progression of metastasis, fate of circulating tumor cells, and in drug development of novel therapies for advanced and drug-resistant tumors. While several individual laboratories can excel at establishing such models, there are challenges, both procedural and technical, which present serious obstacles for established investigators as well as new investigators without prior experience with PDX models. Therefore, for some Institutions it is preferable to designate a centralized “PDX Core” to streamline the workflow that is required for the success of such program. Here we describe and analyze the key components of a successful Academic PDX program. The PDX coordination branch carries out administrative duties to guarantee that the multiple components involved in generating PDXs are seamlessly integrated. In particular, it deals with logistical tasks including regulatory requirements (IRB, patient consent forms, IACUC), and sample accrual (patient selection, coordination with surgery schedules, specimen collection). In addition, it takes care of database maintenance and interface with clinical applications. The PDX laboratory branch meanwhile devises and implements standard operating procedures for sample processing, storage and implantation, and model maintenance, PDX characterization and distribution, and takes care of training of specialized personnel. The establishment of such centralized PDX core at MSKCC resulted in a tenfold increase in the Institution's ability to generate PDX models within a year of inception of the program. In particular, for ongoing projects, we observed an increase not just in sample accrual but also in tumor take rate. In addition, the number of different tumor types implanted expanded substantially, from six to over twenty. PDXs have the potential to be invaluable tools in understanding cancer and developing novel treatments. In our experience, the establishment of a centralized PDX core is both the most cost effective and efficient way for academic investigators to generate and gain access to novel, well characterized, and clinically annotated PDX models. Citation Format: Marissa Mattar, Rajesh K. Uthamanthil, Elisa de Stanchina. Establishment and maintenance of a PDX Core Facility. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B30.
Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy
Authors: C.J. Byrne, J.A. Roberts, B. McWhinney, S.A. Ryder, J.P. Fennell, P. O'Byrne, E. Deasy, S. Egan, R. Desmond, H. Enright, D.M. D'Arcy, J. McHugh
Journal: Clinical Microbiology and Infection (2017)